DACK KEVIN NEIL
No ORCID on file
· 126 papers in corpus
· active 2006-2010
Frequent coauthors
2010
The present invention relates to a class of EP2 antagonistazetidines of general formula (I), wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2010
The present invention relates to a class of EP2 antagonistazetidines of general formula (I), wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2010
The present invention relates to a class of EP2 antagonistazetidines of general formula (I), wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2010
The present invention relates to a class of EP2 antagonistazetidines of general formula (I), wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2010
The present invention relates to a class of EP2 antagonistazetidines of general formula (I), wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2010
The present invention relates to a class of EP2 antagonistazetidines of general formula (I), wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2010
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also rel…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in t…
2009
Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents H, C1-6-alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R2 represents H, C1-6alkyl (optionally substituted by R3), phenyl (optionally substit…